Crohn’s Disease Market Report Insights

 Breaking News
  • No posts were found

Crohn’s Disease Market Report Insights

February 02
16:53 2021
Crohn's Disease Market Report Insights

DelveInsight Business Research LLP
DelveInsight’s “Crohn’s Disease (CD) Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Crohn’s Disease (CD), historical and forecasted epidemiology as well as the Crohn’s Disease (CD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

What is Crohn’s Disease? 

Crohn’s Disease is a type of inflammatory bowel disease (IBD). It is an inflammatory condition of the gastrointestinal tract, which most commonly affects the end of the small bowel (the ileum), the beginning of the colon, and any part of the gastrointestinal (GI) tract from the mouth to the anus.

How many people are affected by Crohn’s Disease?

  • In UK, it is estimated that at least 115,000 people have Crohn’s Disease.
  • Crohn’s Disease can occur at any age and is more prevalent among adolescents and young adults between the ages of 15 and 35.

Crohn’s Disease Treatment

The standardized approved evidence-based therapies for the Crohn’s Disease treatment include infliximab (Remicade; Janssen Biotech), adalimumab (Humira; AbbVie), certolizumab Pegol (Cimzia; UCB), natalizumab (Tysabri; Biogen), vedolizumab (Entyvio; Millennium Pharmaceuticals), and Ustekinumab (Stelara; Janssen Biotech). These therapies have been approved for moderate to severe Crohn’s Disease.


Request for free sample pages @ Crohn’s Disease Market trends


How will Crohn’s Disease Market change in upcoming years? 

The growth of the Crohn’s Disease market include increased understanding of the disease, introduction of novel therapies in the Crohn’s Disease market, and other innovative treatment options to overcome the limitation of the current Crohn’s Disease treatment regimen and improved patient-of-care.

Expected launch of emerging therapies such as AbbVie’s risankizumab, Genentech’s etrolizumab, and other therapies shall increase the market size of Crohn’s Disease.

Crohn’s Disease Emerging Therapies



The launch of emerging therapies such as Filgotinib (Gilead Sciences), Risankizumab (Abbvie), Etrolizumab (Genetech), PDA-001 (Celularity) and other compelling treatments are expected to increase the Crohn’s Disease market size in upcoming years.

Key players such as Gilead Sciences, Celgene Corporation, Abbvie, Genetech, and many others are involved in developing therapies for Crohn’s Disease.


Request for free sample pages @ Crohn’s Disease Market trends


Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States

Related Articles